MTR

Across TCGA pan-cancer cohorts, MTR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTR data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTR mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTR expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where MTR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	27	view →
UCEC	DFS	Quartile	II,III,IV	0.248	1.000	.002	24	view →
LUAD	DFS	Median	All	0.972	0.632	.005	15	view →
HNSC	DFS	Tertile	III,IV	1.000	0.891	.025	5	view →
LSCC	DFS	Median	II,III,IV	0.847	0.988	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTR–CCRCC (DFS)

Open the CCRCC breakdown →